The local mammalian target of rapamycin(mTOR) modulation:a promising strategy to counteract neurodegeneration
|
摘要
<正>Alzheimer's disease(AD)and the evolution of the"Amyloid Hypothesis":The primary risk factor for dementia is aging,as the overwhelming majority of individuals who have the disease(～95%)are 65 years old or older,and the rate of development of AD doubles roughly every five years from that age,peaking at a nearly 50%population prevalence by the age of 85.The disease is progressive
引文
Caccamo A,Majumder S,Richardson A,Strong R,Oddo S(2010)Molecular interplay between mammalian target of rapamycin(mTOR),amyloid-beta,and tau:effects on cognitive impairments.J Biol Chem285:13107-13120.
Cassano T,Magini A,Giovagnoli S,Polchi A,Calcagnini S,Pace L,Lavecchia MA4,Scuderi C,Bronzuoli MR,Ruggeri L,Gentileschi MP,Romano A,Gaetani S,De Marco F,Emiliani C,Dolcetta D(2019)Early intrathecal infusion of everolimus restores cognitive function and mood in a murine model of Alzheimer’s disease.Exp Neurol 311:88-105.
Chapman NM,Chi H(2014)mTOR signaling,Tregs and immune modulation.Immunotherapy 6:1295-1311.
Crino PB(2016)The mTOR signalling cascade:paving new roads to cure neurological disease.Nat Rev Neurol 12:379-392.
Kim YC,Guan KL(2015)mTOR:a pharmacologic target for autophagy regulation.J Clin Invest 125:25-32.
Heneka MT,Carson MJ,El Khoury J,Landreth GE,Brosseron F,Feinstein DL,Jacobs AH,Wyss-Coray T,Vitorica J,Ransohoff RM,Herrup K,Frautschy SA,Finsen B,Brown GC,Verkhratsky A,Yamanaka K,Koistinaho J,Latz E,Halle A,Petzold GC,et al.(2015)Neuroinflammation in Alzheimer’s Disease.Lancet Neurol 14:388-405.
Kurdi A,De Doncker M,Leloup A,Neels H,Timmermans JP,Lemmens K,Apers S,De Meyer GRY,Martinet W(2016)Continuous administration of the mTORC1 inhibitor everolimus induces tolerance and decreases autophagy in mice.Br J Pharmacol 173:3359-3371.
LaFerla FM,Green KN,Oddo S(2007)Intracellular amyloid-beta in Alzheimer’s disease.Nat Rev Neurosci 8:499-509.
Peyrl A,Chocholous M,Azizi AA,Czech T,Dorfer C,Mitteregger D,Gojo J,Minichmayr E,Slavc I(2014)Safety of Ommaya reservoirs in children with brain tumors:a 20-year experience with 5472 intraventricular drug administrations in 98 patients.J Neurooncol 120:139-145.
Petersen RC(2018)How early can we diagnose Alzheimer disease(and is it sufficient)?The 2017 Wartenberg lecture.Neurology 91:395-402.
SantaCruz KS,Sonnen JA,Pezhouh MK,Desrosiers MF,Nelson PT,Tyas SL(2012)Alzheimer disease pathology in subjects without dementia in two studies of aging:the nun study and the adult changes in thought study.J Neuropathol Exp Neurol 71:362-381.
Selkoe DJ,Hardy J(2016)The amyloid hypothesis of Alzheimer’s disease at25 years.EMBO Mol Med 8:595-608.
Cassano T,Magini A,Giovagnoli S,Polchi A,Calcagnini S,Pace L,Lavecchia MA4,Scuderi C,Bronzuoli MR,Ruggeri L,Gentileschi MP,Romano A,Gaetani S,De Marco F,Emiliani C,Dolcetta D(2019)Early intrathecal infusion of everolimus restores cognitive function and mood in a murine model of Alzheimer’s disease.Exp Neurol 311:88-105.
Chapman NM,Chi H(2014)mTOR signaling,Tregs and immune modulation.Immunotherapy 6:1295-1311.
Crino PB(2016)The mTOR signalling cascade:paving new roads to cure neurological disease.Nat Rev Neurol 12:379-392.
Kim YC,Guan KL(2015)mTOR:a pharmacologic target for autophagy regulation.J Clin Invest 125:25-32.
Heneka MT,Carson MJ,El Khoury J,Landreth GE,Brosseron F,Feinstein DL,Jacobs AH,Wyss-Coray T,Vitorica J,Ransohoff RM,Herrup K,Frautschy SA,Finsen B,Brown GC,Verkhratsky A,Yamanaka K,Koistinaho J,Latz E,Halle A,Petzold GC,et al.(2015)Neuroinflammation in Alzheimer’s Disease.Lancet Neurol 14:388-405.
Kurdi A,De Doncker M,Leloup A,Neels H,Timmermans JP,Lemmens K,Apers S,De Meyer GRY,Martinet W(2016)Continuous administration of the mTORC1 inhibitor everolimus induces tolerance and decreases autophagy in mice.Br J Pharmacol 173:3359-3371.
LaFerla FM,Green KN,Oddo S(2007)Intracellular amyloid-beta in Alzheimer’s disease.Nat Rev Neurosci 8:499-509.
Peyrl A,Chocholous M,Azizi AA,Czech T,Dorfer C,Mitteregger D,Gojo J,Minichmayr E,Slavc I(2014)Safety of Ommaya reservoirs in children with brain tumors:a 20-year experience with 5472 intraventricular drug administrations in 98 patients.J Neurooncol 120:139-145.
Petersen RC(2018)How early can we diagnose Alzheimer disease(and is it sufficient)?The 2017 Wartenberg lecture.Neurology 91:395-402.
SantaCruz KS,Sonnen JA,Pezhouh MK,Desrosiers MF,Nelson PT,Tyas SL(2012)Alzheimer disease pathology in subjects without dementia in two studies of aging:the nun study and the adult changes in thought study.J Neuropathol Exp Neurol 71:362-381.
Selkoe DJ,Hardy J(2016)The amyloid hypothesis of Alzheimer’s disease at25 years.EMBO Mol Med 8:595-608.